© G.K.Raju, Ph.D. Manufacturing Science Sept 17th 2003 QUALITY BY DESIGN: The Means To Fundamental Manufacturing Science G.K.Raju, Ph.D.

Slides:



Advertisements
Similar presentations
CONTINUOUS QUALITY VERIFICATION (CQV) G. K. Raju, Ph. D
Advertisements

1 The Potential For Implementing Demand Response Programs In Illinois Rick Voytas Manager, Corporate Analysis Ameren Services May 12, 2006.
Atypical Actives PDA-FDA Conference March 9-10, 2011 David R. Schoneker
Methods of tablet manufacturing
And Learning TEAL Consulting Limited a a Meeting Customer Demand in Challenging Times July 2010.
How to Define Design Space Lynn Torbeck. Overview Why is a definition important? Definitions of Design Space. Deconstructing Q8 Definition. Basic science,
Process Analytical Technologies Subcommittee Product and Process Development: An Industry Perspective David Rudd PhD Process Technology GlaxoSmithKline.
Pilot Risk-Ranking Model to Prioritize Manufacturing Sites for GMP Inspections Advisory Committee for Pharmaceutical Science Manufacturing Subcommittee.
Ray Scherzer FDA ACPS October 26, 2005 Breaking with Tradition: The Manufacturing Challenges Ahead!
Global Quality Operations
MIT PHARMACEUTICAL MANUFACTURING INITIATIVE (PHARMI) PHARMACEUTICAL MANUFACTURING: NEW TECHNOLOGY OPPORTUNITIES.. G.K.Raju, Ph.D. Executive Director, Pharmaceutical.
1 GMP issues in Q assessment Wondiyfraw Worku Assessor 6 th CPH assessment training workshop, May 2014.
Capability Maturity Model
Challenges and Opportunities in Enhancement of the CMC Section of NDAs: Quality – by - Design Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.
Final Report on Process Analytical Technology (PAT) and Manufacturing Science Ajaz S. Hussain, Ph.D. Deputy Director, Office of Pharmaceutical Science,
Learnings from Pre-approval Joint Inspection of a GSK QbD Product with US-FDA & EMA and the application of Continuous Verification 17 May 2011, Beijing,
Ensuring Physical Stability of Pharmaceuticals: Can/should we improve our ability to identify and prevent physical changes? Ajaz S. Hussain, Ph.D. Deputy.
Quality By Design and Dissolution PhRMA 10/25/05
Xcellerex … speeding medicines to people … PAT for Biologics Ensuring Quality of Biologically Produced Drugs FDA Advisory Committee on Pharmaceutical Sciences.
Application of the principles of QbD in vaccines production Andrea Pranti.
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
Outline Thought for the day! Acknowledgements Top issues
Slide 1 May 2008 Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008 QUALITY BY DESIGN.
N By: Md Rezaul Huda Reza n
Quality by Design Application of Pharmaceutical QbD for Enhancement of the Solubility and Dissolution of a Class II BCS Drug using Polymeric Surfactants.
D. Christopher Watts, Ph.D. Office of Pharmaceutical Science, CDER, FDA Science Seminar Series for the Office of Commissioner April 9, 2004 Process Analytical.
Module 1, Part 3: Process validation Slide 1 of 22 © WHO – EDM – 12/2001 Validation Part 3: Process validation Supplementary Training Modules on Good Manufacturing.
Sultan Ghani WHO Prequalification Programme of Priority Essential Medicines, October 2010, Abu Dhabi, U.A.E. Dossier Requirements for Generic Medicines.
FDA Regulation of Drug Quality: New Challenges Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research, Food and Drug Administration April.
Quality by Design (QbD) Myth : An expensive development tool ! Fact : A tool that makes product development and commercial scale manufacturing simple !
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
1 An Update on ICH Guideline Q8 – Pharmaceutical Development FDA Advisory Committee for Pharmaceutical Science: 5 Oct 2006 Dr John C Berridge Senior Regulatory.
Quality by Design & Question-Based Review: Observations by the Generic Pharmaceutical Industry Advisory Committee for Pharmaceutical Science October 5,
Objectives of Performance Measures 1.Establish base line measures and reveals trends 2.Determine which processes need to be improved 3.Indicate process.
Critical Material Properties for Pharmaceutical Dosage Forms - Industry Perspective Tony Hlinak Abbott Laboratories North Chicago, IL.
1 Basis of the Proposed Tactical Plan for a QbD approach for Quality Control and Assurance of Dissolution Rate Ajaz S. Hussain, Ph.D. Deputy Director,
What Impact should ICH Q8 have on ICH Q6A Decision Trees?
Small molecules Liquids – Solvent composition – Reactions – HME Dry Powder – Blending – Dry Granulation – Dry milling Wet solids – API Crystallization.
Molecule-to-Market-Place Quality
Purdue University – Industrial and Physical Pharmacy - Morris Discussion Questions of Polymorphism in ANDAs Ken Morris Industrial and Physical Pharmacy.
Some Future Developments Brian Carlin, Ph.D FMC Chris Moreton, Ph.D FinnBrit Consulting IPEC-Americas FDA Seminar, October 21,
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
10:00 A.M. – Noon 7 June 2004 ICH Quality Plenary Meeting.
FDA PROCESS ANALYTICAL TECHNOLOGY SUB COMMITTEE MEETING 25 TH FEBRUARY 2002 PERSPECTIVE ON PROCESS AND ANALYTICAL VALIDATION Robert S Chisholm.
© G.K.Raju, Ph.D. Confidential FDA Manufacturing Subcommittee Meeting July 20, 2004 G.K. Raju, Ph.D. Executive Director, MIT/PHARMI Massachusetts Institute.
Master Formula And Batch MaNUFACTURING Record
Bioavailability of Dietary Supplements: Key Issues in Defining the Research Agenda Impact of Formulation on Bioavailability? Discussion Leader: Stephen.
FDA PAT Sub-Committee of Advisory Committee for Pharmaceutical Sciences June 12-13, 2002; Gaithersburg, MD Regulatory Challenges: Post-Approval PAT Applications.
Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,
Topic #2: Quality by Design and Pharmaceutical Equivalence Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Science Center for Drug Evaluation and Research.
© G.K.Raju, Ph.D. Manufacturing Science May 21st 2003 MANUFACTURING SCIENCE: The Means To GMPs In the 21 st Century.. G.K.Raju, Ph.D.
开发报批美国 FDA 的仿制药 与相关问题探讨 上海复星普适医药科技有限公司何平. 内容提要 开发仿制药的重要性和机遇 开发仿制药的重要性和机遇 开发仿制药的挑战 开发仿制药的挑战 申报仿制药的分类 申报仿制药的分类 仿制药研发团队 仿制药研发团队 仿制药的研发过程 仿制药的研发过程 QbD 在制剂开发中怎么体现.
QbD Technologies: Workshop for Risks Management Incorporating Risk Management for Technology Transfer.
Regulatory Labeling and Marketing. Which ones are involved in label design and control? Manufacturing Manufacturing Quality Assurance Quality Assurance.
Product & Process Working Group February 26, 2002.
QbD Technologies: Workshop for Risks Management Incorporating Risk Management for Technology Transfer.
CEM515QUALITYASSURANCECEM515QUALITYASSURANCE SUPPLIER PARTNERSHIP.
Integration of Excipients into the Design of Experiments for Pharmaceutical Product and Design Space Development Chris Moreton, Ph.D. FinnBrit Consulting.
HOLD-TIME STUDIES.
MOSH Adoption Team Training
An Update on ICH Guideline – Pharmaceutical Development
Quality Metrics for better Quality Compliance
Enabling direct compaction at high drug loading via dry coating of APIs: Towards a predictive framework Presenter(s): Kuriakose T. Kunnath, NJIT Research.
Uncontrolled variation is the enemy of quality
MDIC- Case for Quality Forum
QUALITY BY DESIGN Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008.
SUPPLIER PARTNERSHIP 2.
What are the opportunities and obstacles to using patient feedback in service improvement? Laura Sheard, PhD Bradford Teaching Hospitals 30th January.
Quality by Design.
Chapter 14 Sourcing Decisions in a Supply Chain
Presentation transcript:

© G.K.Raju, Ph.D. Manufacturing Science Sept 17th 2003 QUALITY BY DESIGN: The Means To Fundamental Manufacturing Science G.K.Raju, Ph.D.

© G.K.Raju, Ph.D. Manufacturing Science OUTLINE l MOTIVATION l “MANUFACTURING SCIENCE”: DIMENSIONS l QUALITY BY DESIGN: THE LEVERAGES l QUALITY BY DESIGN: THE COMPONENTS l CONSIDERATIONS

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SYSTEM” A “manufacturing system” is set of processes and systems (and people) bound by a common material and information flow. Material Information WEIGH WET GRANULN STEPFB DRY STEP BLEND ENCAPSULATE SIEVE QC 1 QC 3 QC 4 DRY MIX QC 2

© G.K.Raju, Ph.D. Manufacturing Science ACTIVE FORMULNFILL PACK ACTIVE FORMULNFILLPACK ACTIVE FORMULNFILLPACK RESEARCH DEVELOPMENT MANUFACTURING TIME SPACE PHARMACEUTICAL MANUFACTURING SYSTEM COST QUALITY TIME SAFETY

© G.K.Raju, Ph.D. Manufacturing Science PROCESS A WITH QC TESTS WEIGHING WET GRANULATION STEPFB DRY STEP BLEND ENCAPSULATESIEVE API MICRO Particle Size Description ID Assay CU Impurity Dissolution MICRO QC 1 QC 3 QC 4 DRY MIX QC 2 LOD

© G.K.Raju, Ph.D. Manufacturing Science QUALITY “TESTING” END OF LINE CONSUMES SIGNIFICANT TIME TIME (Days) ABCDEF Overall Cycle Time Components Process Times QC Testing Times

© G.K.Raju, Ph.D. Manufacturing Science QUALITY “TESTING” END OF LINE MAKES IT DIFFICULT TO UNDERSTAND “EXCEPTIONS” LOT NUMBER OVERALL CYCLE TIMES Lots without Exceptions Lots with Exceptions

© G.K.Raju, Ph.D. Manufacturing Science PHARMA MANUFACTURING CYCLE TIMES (DAYS): HALF A YEAR, LITTLE IMPROVEMENT…. * Derived from COGS numbers

© G.K.Raju, Ph.D. Manufacturing Science OUTLINE l MOTIVATION l “MANUFACTURING SCIENCE”: DIMENSIONS l QUALITY BY DESIGN: THE LEVERAGES l QUALITY BY DESIGN: THE COMPONENTS l CONSIDERATIONS

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE”: DIMENSIONS Body of Knowledge, Laws, Principles Involved In The Transformation of Materials and Information into Goods for the Satisfaction of Human Needs Extent Of Mfg. Science

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE” : Levels of Knowledge Extent Of Mfg. Science Or Quality By Design LEVEL 1 LEVEL 2 LEVEL 4 LEVEL 5 LEVEL 3 PROCESS KNOWLEDGE How, Correlative.. CAUSAL KNOWLEDGE Why? MECHANISTIC KNOWLEDGE First Principles DESCRIPTIVE KNOWLEDGE: What, Etc, …

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE”: The “Time” Dimension THE DESIRED STATE Extent Of Mfg. Science Time “Right First Time” LEVEL 1 LEVEL 2 LEVEL 4 LEVEL 5 LEVEL 3 FDA Minimum Requirement Manufacturing Centric Approach to Manufacturing Science (“learning by doing”) Design/Development Centric Approach Manufacturing Science (“learning before doing”)

© G.K.Raju, Ph.D. Manufacturing Science “EXTENT OF MANUFACTURING SCIENCE”: COST, QUALITY AND TIME OPPORTUNITY Extent Of Mfg. Science Time “Right First Time” LEVEL1 LEVEL2 LEVEL 4 LEVEL5 LEVEL3 FDA Minimum Requirement Manufacturing Centric Approach to Manufacturing Science (“learning by doing”) Design/Development Centric Approach Manufacturing Science (“learning before doing”) Cost Quality Time Opportunity Desired Actual

© G.K.Raju, Ph.D. Manufacturing Science OUTLINE l MOTIVATION l “MANUFACTURING SCIENCE”: DIMENSIONS l QUALITY BY DESIGN: THE LEVERAGES l QUALITY BY DESIGN: THE COMPONENTS l CONSIDERATIONS

© G.K.Raju, Ph.D. Manufacturing Science QUALITY BY DESIGN: THE LEVERAGES Extent Of Mfg. Science Or Quality By Design Time “Right First Time” LEVEL1 LEVEL2 LEVEL 4 LEVEL5 LEVEL3 FDA Minimum Requirement Manufacturing Centric Approach to Manufacturing Science (“learning by doing”) Design/Development Centric Approach Manufacturing Science (“learning before doing”) Strategic Leverage Tactical Leverage

© G.K.Raju, Ph.D. Manufacturing Science QUALITY BY DESIGN: STRATEGIC LEVERAGE: “Learning Before Doing” l Significantly Enhanced Level of Product & Process Understanding BEFORE Commercial Manufacturing l Enables Mechanistic Basis for Setting Product and Process Quality Specifications l Impact Over Whole Lifecycle l Easier to Make Fundamental Process Design Changes (Fewer Regulatory Barriers)

© G.K.Raju, Ph.D. Manufacturing Science QUALITY BY DESIGN: STRATEGIC LEVERAGE: “Learning By Doing” l Enhanced Level of Product & Process Understanding DURING Commercial Manufacturing l Potential To Leverage Large Amounts of Production Data l Investigation/Exceptions Provide Opportunity To Learn l Difficult to Make Significant Product & Process Changes l Rarely an environment to develop mechanistic understanding

© G.K.Raju, Ph.D. Manufacturing Science WEIGHING GRANULATION FB DRY MILLING BLEND FILM COATING COMPRESS BOTTLE PACKAGING LEVEL 1: INITIAL WEIGHING GRANULATION FB DRY MILLING BLEND FILM COATING COMPRESS BOTTLE PACKAGING LEVEL 2: REPEATABLE WEIGHING GRANULATION FB DRY MILLING BLEND FILM COATING COMPRESS BOTTLE PACKAGING LEVEL 4: MANAGED LEVEL 5: OPTIMIZING WEIGHINGBLEND FILM COATING COMPRESS BOTTLE PACKAGING WEIGHING GRANULATION FB DRY MILLING BLEND FILM COATING COMPRESS BOTTLE PACKAGING LEVEL 3: DEFINED QUALITY BY DESIGN: A PROCESS ROADMAP

© G.K.Raju, Ph.D. Manufacturing Science OUTLINE l MOTIVATION l “MANUFACTURING SCIENCE”: DIMENSIONS l QUALITY BY DESIGN: THE LEVERAGES l QUALITY BY DESIGN: THE COMPONENTS l CONSIDERATIONS

© G.K.Raju, Ph.D. Manufacturing Science PROCESS & PRODUCT Y = F(X) Performance Measurement A-priori knowledge Information Exchange QUALITY BY DESIGN: COMPONENTS Extent Of Manufacturing Science Or Quality By Design

© G.K.Raju, Ph.D. Manufacturing Science lHow Much Was Known About This Product & Process Before? u API u Excipients u Etc. lWhat Kind of “A-Priori Knowledge” Exists? u First Principle Knowledge u Mechanistic Knowledge u Causal Knowledge u Correlative Knowledge u Descriptive Knowledge COMPONENTS OF “QUALITY BY DESIGN: A-PRIORI KNOWLEDGE

© G.K.Raju, Ph.D. Manufacturing Science Current ApproachProposed Approach x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x xx x x xxx x x x x x x x x x x x x x x x x x x x x x x x x x xx x x xxx x x x x x x x x Process Development Commercial Production 1a 1b 2a 2b COMPONENTS OF “QUALITY BY DESIGN: INFORMATION EXCHANGE: EXTENT AND TYPE WHAT IS THE QUALITY AND QUANTITY OF DATA USED

© G.K.Raju, Ph.D. Manufacturing Science ON-LINE TECHNOLOGY IMPACTS DOMINANT CYCLE TIMES On-line LIF, NIR, Pattern Recognition, etc.

© G.K.Raju, Ph.D. Manufacturing Science CURRENT STATE WEIGHING GRANULATION FB DRY MILLING BLEND FILM COATING COMPRESS BOTTLE PACKAGING LEVEL 1: INITIAL WEIGHING GRANULATION FB DRY MILLING BLEND FILM COATING COMPRESS BOTTLE PACKAGING LEVEL 2: REPEATABLE WEIGHING GRANULATION FB DRY MILLING BLEND FILM COATING COMPRESS BOTTLE PACKAGING LEVEL 4: MANAGED LEVEL 5: OPTIMIZING WEIGHINGBLEND FILM COATING COMPRESS BOTTLE PACKAGING WEIGHING GRANULATION FB DRY MILLING BLEND FILM COATING COMPRESS BOTTLE PACKAGING LEVEL 3: DEFINED Minimum Requirement “MANUFACTURING SYSTEM” ROADMAP: CURRENT Relative To DESIRED State

© G.K.Raju, Ph.D. Manufacturing Science l Safety and Efficacy l Process Capability Associated With Critical- To-Quality (CTQ) Variables l Variability of Critical-To-Quality Variables l Predictive Ability Of Performance COMPONENTS OF “QUALITY BY DESIGN: PERFORMANCE MEASUREMENT

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE”: DESIRED RELATIVE TO CURRENT STATE (Personal Opinion) Extent Of Mfg. Science Time “Right First Time” LEVEL1 LEVEL2 LEVEL 4 LEVEL5 LEVEL3 FDA Minimum Requirement Manufacturing Centric Approach to Manufacturing Science (“learning by doing”) Design/Development Centric Approach Manufacturing Science (“learning before doing”)

© G.K.Raju, Ph.D. Manufacturing Science OUTLINE l MOTIVATION l “MANUFACTURING SCIENCE”: DIMENSIONS l QUALITY BY DESIGN: THE LEVERAGES l QUALITY BY DESIGN: THE COMPONENTS l CONSIDERATIONS

© G.K.Raju, Ph.D. Manufacturing Science QUALITY BY DESIGN: IS THE EXTENT OF “RIGHT FIRST TIME” Time (& cost) Associated With Addressing Cause For Not Being “Right” Where “Right” is Measured DEVELOPMENT WARNING LETTER FDA 483 RECALLS COMPLAINTS FINAL QC TESTING QA APPROVAL IN-PROCESS TESTING REJECTS CONSENT DECREE Prevention Appraisal Internal Failure External Failure Common Focus

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE” : IMPLICATIONS Extent Of Mfg. Science Or Quality By Design LEVEL1 LEVEL2 LEVEL4 LEVEL 5 LEVEL3 PROCESS KNOWLEDGE How, Correlative.. CAUSAL KNOWLEDGE Why? MECHANISTIC KNOWLEDGE First Principles DESCRIPTIVE KNOWLEDGE: What, Etc, … LEVEL5 Lower Risk Higher Process Understanding Lower Variability Lower Costs

© G.K.Raju, Ph.D. Manufacturing Science “MANUFACTURING SCIENCE” : IMPLICATIONS Extent Of Mfg. Science Or Quality By Design LEVEL1 LEVEL2 LEVEL4 LEVEL3 PROCESS KNOWLEDGE How, Correlative.. CAUSAL KNOWLEDGE Why? MECHANISTIC KNOWLEDGE First Principles DESCRIPTIVE KNOWLEDGE: What, Etc, … LEVEL5 FDA